Beam Therapeutics

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.

Our dream is to provide life-long cures for patients suffering from serious diseases.

The Beam Team Is:
• A community of fearless innovators
• Rigorous and honest in our research
• Listening with open minds
• Committed to each other